Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab vs rATG in Renal Transplant Recipients
NCT07508787Phase 2Recruiting
- Sponsor
- Nefro Avillion Clinical Development Limited
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of siplizumab in renal transplant rejection (RTR) (3 arms), sponsored by Nefro Avillion Clinical Development Limited. Primary endpoint: Assessment of the safety of 2 dose levels of siplizumab versus rATG at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
siplizumab
03
Conditions
renal transplant rejection (RTR)
Beyond the preview
Go deeper on NCT07508787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508787.